Last updated: February 21, 2026
What is the drug associated with NDC 69339-0136?
The drug identified by NDC 69339-0136 is Aflibercept, marketed under the brand name Eylea. It is a vascular endothelial growth factor (VEGF) inhibitor used primarily to treat:
- Wet age-related macular degeneration (AMD)
- Diabetic macular edema (DME)
- Central retinal vein occlusion (CRVO)
- Myopic choroidal neovascularization
Current Market Landscape
Market Size and Revenue
Eylea remains a leading intraocular anti-VEGF therapy. Its market is driven by the aging population and increasing prevalence of retinal diseases.
- In 2022, global sales exceeded $9 billion [1].
- U.S. market share accounts for approximately 50% of global revenue [2].
Competitors
Primary competitors include:
| Drug |
Indications |
2022 U.S. Sales |
Market Share (U.S.) |
Price per Dose |
| Eylea |
AMD, DME, CRVO |
$4.5 billion |
50% |
$2,000 - $2,300 |
| Lucentis |
AMD, DME |
$2.8 billion |
31% |
$2,100 - $2,400 |
| Beovu |
AMD, DME |
$540 million |
6% |
$1,900 - $2,100 |
Market Dynamics
- The anti-VEGF market growth rate hovers around 5-7% annually.
- New entrants and biosimilars are slowly emerging but are hindered by patent protections.
- Insurance and drug rebate programs influence net prices.
Regulatory Status and Patent Outlook
Eylea was approved by the U.S. Food and Drug Administration (FDA) in 2011. Its primary patent is valid until 2024, with some extensions possible through formulation patents and secondary protections.
Patent expiration could lead to biosimilar competition, potentially reducing prices.
Price Projections
Historical Pricing Trends
- Initial wholesale acquisition cost (WAC) per dose: approximately $1,950 - $2,200 in 2012.
- Over the last decade, prices have slightly increased, aligning with inflation and R&D costs.
Near-term Price Outlook
- 2023-2025: Prices are expected to stabilize, barring biosimilar entry. Prices may hover between $2,000 and $2,300 per dose.
- Post-2024: Introduction of biosimilars could reduce prices by 20-40%, depending on market adoption and payor negotiations.
Cost Factors Influencing Prices
- Manufacturing costs: high due to complex biologic production.
- Market penetration: influenced by physician prescribing habits and insurance coverage.
- Regulatory approvals: biosimilar approval pathways in the U.S. could accelerate price reductions.
Volume and Revenue Projections
| Year |
Estimated Prescriptions |
Estimated Revenue |
Notes |
| 2023 |
10 million doses |
$20 billion |
Stable prices anticipated |
| 2024 |
11 million doses |
$22 billion |
Patent expiry impact begins |
| 2025 |
12 million doses |
$24 billion |
Biosimilar entry could begin affecting prices |
Risks to Price Projections
- Patent challenges or legal delays could extend exclusivity.
- Regulatory approval of biosimilars may lower prices further.
- Changes in insurance reimbursement policies may impact net patient costs.
Summary
Eylea (NDC 69339-0136) holds a dominant position in the intravitreal anti-VEGF market, with stable pricing expected through 2023 due to patent protections. The entry of biosimilars post-2024 is likely to exert downward pressure on prices, potentially reducing per-dose costs by 20-40%. Market volume growth is steady, driven by increasing prevalence of retinal diseases and aging demographics.
Key Takeaways
- The current price per dose hovers around $2,000 - $2,300.
- Patent expiration in 2024 risks significant price erosion.
- Market share remains concentrated with Eylea, but biosimilar competition is emerging.
- Revenue projections suggest continued growth, contingent on volume increases and price stability.
- Biosimilar approvals could reshape the competitive landscape and pricing in the mid-2020s.
FAQs
-
What factors most influence the price of Eylea?
Manufacturing complexity, patent protections, market competition, and insurance reimbursement policies.
-
When will biosimilars for Eylea likely enter the market?
Biosimilar applications have been filed, with approvals expected around 2024-2025, contingent on regulatory review.
-
How does the patent landscape affect future pricing?
Patent expiry in 2024 could allow biosimilar competition, reducing prices significantly.
-
Are there regional differences in Eylea pricing?
Yes. Prices vary by country based on local regulations, reimbursement schemes, and negotiated discounts.
-
What is the potential impact of biosimilar entry on the existing market?
Biosimilars could capture a substantial share, reducing prices by up to 40%, and increasing overall market volume.
References
[1] IQVIA. (2022). Pharmaceutical Market Data.
[2] Statista. (2022). Global sales of anti-VEGF therapies.
[3] U.S. Food and Drug Administration. (2011). Eylea (Aflibercept) approval letter.
